Teclistamab Dosing and Adverse Event Prophylaxis Practices
Following a review of recent data from MajesTEC-1 investigating teclistamab, the panel provides clinical insights on dosing and adverse event prophylaxis practices.
EP: 1.The Current Treatment Landscape for Relapsed/Refractory Multiple Myeloma
EP: 2.MajesTEC-1: Efficacy and Safety of Teclistamab
Now Viewing
EP: 3.Teclistamab Dosing and Adverse Event Prophylaxis Practices
EP: 4.Clinical Implications of MajesTEC-1
EP: 5.Long-Term Data Affirm Enduring Responses With Teclistamab in R/R Multiple Myeloma
Video content above is prompted by the following question(s):
- What factors could contribute to the observed decrease in the onset of new grade ≥3 infections over time, and what are the clinical implications?
Recent Videos
Related Content
